ArticlePLoS neglected tropical diseases2026
Epidemiological transitions of Visceral Leishmaniasis in G20 countries: A 33-year retrospective joinpoint and demographic decomposition analysis with 20-year ARIMA projections.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral leishmaniasis (VL) remains a fatal neglected tropical disease with substantial global burden. The Group of Twenty (G20) encompasses both endemic and non-endemic nations, yet comprehensive multi-country assessments of VL trends and future projections are limited. This study aims to evaluate the 33-year epidemiological transition of VL across G20 countries and forecast its trajectory to 2043. METHODOLOGY/PRINCIPAL
findingsWe extracted VL-related prevalence, incidence, mortality, and disability-adjusted life years (DALYs) data for G20 countries from the Global Burden of Disease 2023 database (1990-2023). We employed joinpoint regression to identify trend inflection points, decomposition analysis to quantify drivers of change (population growth, aging, and epidemiological changes), and autoregressive integrated moving average (ARIMA) models to project trends to 2043. From 1990 to 2023, G20 countries showed significant declines in age-standardized prevalence rate (EAPC = -9.06%), incidence rate (EAPC = -9.06%), mortality rate (EAPC = -7.23%), and DALYs rate (EAPC = -7.40%). Saudi Arabia, Turkey, and India experienced the steepest declines, while Brazil exhibited the smallest reduction and the highest burden in 2023 (age-standardized DALY rate: 30.54 per 100,000). Burden was consistently higher in males and concentrated in children under 5 years, with a slight increase observed among those aged ≥95 years. Decomposition analysis revealed that changes in epidemiological rates were the primary driver of mortality (contributing -82.05%) and DALYs (-52.62%) reductions, counteracting the positive effects of population growth and aging. ARIMA projections (2024-2043) suggest a stabilization in mortality, a gradual decline in DALYs, and a subtle increase in incidence and prevalence rates, with persistent gender disparities. CONCLUSIONS/SIGNIFICANCE: While the VL burden in G20 nations has significantly decreased, substantial national disparities are evident. Our analysis specifically identifies Brazil as the priority target for intensified control. Sustained surveillance and international cooperation are crucial to prevent a projected mild resurgence in new infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.